Seeking Alpha

Cardiovascular Systems (CSII +11%) rallies after the company says Orbit II trials of its...

Cardiovascular Systems (CSII +11%) rallies after the company says Orbit II trials of its treatment therapy for patients with severely calcified coronary lesions had exceeded expectations by a significant margin. The study is reviewing the safety and effectiveness of it's orbital atherectomy technology and is the first Investigational Device Exemption study to seek approval for treating these lesions.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)